ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Intermittent dosing of Abl inhibitors works well for treatment of CML (Shah et al., 2008) but it is possible that more constant serum concentrations will be needed to produce an effect in neurodegenerative disorders.